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OBJECTIVES This study was designed to determine whether therapy with vasodilators and diuretics,
designed to normalize loading conditions in decompensated heart failure (HF), reduces
neurohormonal activation in the short term.
BACKGROUND Elevated vasoactive neurohormone levels in chronic HF have adverse prognostic impact and
may be targeted by specific therapies.
METHODS Endothelin-1, catecholamines, renin, aldosterone, angiotensin and atrial natriuretic peptides
(ANP, N-ANP and BNP) were measured in 34 patients with advanced HF before and after
hemodynamically guided therapy with vasodilators and diuretics. The therapy was designed
to reduce filling pressures and systemic vascular resistance (SVR) without inotropic therapy.
Blood was drawn before therapy (A), after initial diuretic and nitroprusside therapy to
optimize hemodynamics (B, mean 1.4 days) and after transition to an oral regimen designed
to maintain improved hemodynamics (C, mean 3.4 days).
RESULTS Mean pulmonary wedge pressure fell from 31 to 18 mm Hg, right atrial pressure from 15 to
8 mm Hg, and SVR from 1,780 to 1,109 dynes/s/cm5. Cardiac index increased from 1.7 to
2.6 l/min/m2 without intravenous inotropic agents (all p  0.05). Average endothelin levels
declined by 30%, from 7.7 to 5.5 pg/ml, and remained low at time point C, 5.2 pg/ml (p 
0.01). Norepinephrine was 858 at time A, 817 at time B, and fell by time C to 608 pg/ml (p
0.05). The mean plasma BNP level fell by 26% after only 1.4 days and by 53% at time C (p
0.001).
CONCLUSIONS Neurohormonal activation rapidly decreases after short-term therapy tailored to decrease
severely elevated filling pressures and SVR without inotropic agents. Therapy designed to
address neurohormonal activation should include therapy to improve severe resting hemo-
dynamic compromise. (J Am Coll Cardiol 2002;39:1623–9) © 2002 by the American
College of Cardiology Foundation
Symptomatic chronic heart failure (HF) is associated with
an elevation of vasoactive plasma neurohormone levels,
including norepinephrine, endothelin, atrial natriuretic pep-
tide (ANP) and brain natriuretic peptide (BNP). This
neurohormonal activation is emerging as an important
prognostic marker in patients with HF (1–5). Atrial natri-
uretic peptide and BNP are endogenous vasodilators,
whereas norepinephrine and endothelin exert vasoconstric-
tor effects. Many of the current strategies for HF therapy are
specifically targeted to decrease aspects of neurohormonal
activation. Long-term treatment with neurohormonal an-
tagonists improves neurohormonal profiles in patients with
HF (6–8). Direct hemodynamic improvement with a left
ventricular (LV) assist device lowered plasma levels of
norepinephrine and ANP over a three-month period (9).
Although these long-term alterations have been demon-
strated in response to therapy, it is less clear to what extent
the neurohormonal profile can be modified acutely by
improving the hemodynamics. This may be most relevant in
New York Heart Association (NYHA) class IV patients,
where resting hemodynamics are markedly abnormal. In-
tensive HF therapy tailored to reduce filling pressures and
systemic vascular resistance has been associated with an
acute decrease in mitral regurgitation and an increase in
forward cardiac output. The hypothesis of this study is that
intensive medical therapy designed to normalize loading
conditions in decompensated HF acutely reduces neurohor-
monal activation, decreasing plasma levels of norepineph-
rine and endothelin as well as BNP and ANP.
METHODS
Study population. Consecutive patients with chronic HF
who were admitted for treatment of decompensation using
hemodynamic monitoring were identified. Subjects were
excluded if: 1) their ejection fraction was 35% or their
symptoms had been present 6 months; 2) they had
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untreated thyroid disease, myocardial infarction within six
months or a history of drug or alcohol abuse; or 3) they
required intravenous inotropic therapy. All patients except
one with intolerance were receiving enalapril or captopril.
None was taking beta-blocking agents at the time of
admission. All participants gave written, informed voluntary
consent. The study was approved by the Human Research
Committee of Brigham and Women’s Hospital.
Therapy for hemodynamic goals. Treatment of these
patients began with empiric diuresis to reduce obvious
volume reservoirs such as anasarca and ascites when present.
Subsequently, a pulmonary artery catheter was inserted into
an internal jugular or subclavian vein under sterile condi-
tions and local anesthetic (1% lidocaine). Baseline measure-
ments were made to document systemic blood pressure,
right atrial pressure, pulmonary capillary wedge pressure,
pulmonary artery pressure, cardiac output, systemic vas-
cular resistance and pulmonary vascular resistance. A
combination of nitroprusside and diuretics was used to
approach the following hemodynamic goals: right atrial
pressure 8 mm Hg, pulmonary capillary wedge pressure
15 mm Hg and systemic vascular resistance between
1,000 and 1,200 dynes/s/cm5, while maintaining a systolic
blood pressure 80 mm Hg (10). Angiotensin-converting
enzyme (ACE) inhibitors were not administered during
nitroprusside titration. As these goals were approximated,
nitroprusside was weaned and oral vasodilators were re-
instituted and up-titrated to maintain the hemodynamics
achieved. Initially, captopril was given at a dose of 6.25 mg
orally every 8 h and titrated upwards to 25 to 75 mg every
6 to 8 h as guided by optimal hemodynamics defined earlier,
as the nitroprusside was weaned. If necessary to maintain
optimal loading conditions, oral isosorbide dinitrate was
added 10 mg three times daily and increased as necessary.
Hydralazine was initiated, if necessary, to supplement va-
sodilation. The dosing regimens established at the end of
therapy closely approximated the patients’ regimens at
discharge from the hospital.
Sample collection and analysis. Neurohormonal measure-
ments were made before the initiation of nitroprusside, with
each patient maintaining his/her baseline oral regimen until
the morning of catheterization, except for intravenous
diuretics (time point A), after optimal hemodynamics were
approximated on intravenous medication (time point B) and
again after patients had been converted to an oral vasodila-
tor regimen (time point C). On average, the time from A to
B was 1.4  0.2 (mean  standard error) days. The time
from A to C was 3.4 0.4 days. All 34 subjects had samples
obtained at time point A, 22 of those had samples obtained
at time point B, and 28 at time point C. All subjects had at
least two measurements. Measurements were missed be-
cause of patient request, lack of access to sample preparation
room during off-hours or unplanned discontinuation of the
catheter.
All blood samples were drawn at least 2 h after catheter
placement, with the subject supine and resting quietly for at
least 30 min. Samples were drawn from the right atrial port.
Those for ANP, BNP, N-ANP, endothelin and norepi-
nephrine were placed in chilled tubes containing ethyl-
enediaminetetraacetic acid and immediately placed on ice.
They were centrifuged at 4°C within 30 min, quick frozen
and stored at 70°C until analyzed. Atrial natriuretic
peptide and the N-terminal fragment of the ANP prohor-
mone (N-ANP) were measured by radioimmunoassay as
previously described (3); BNP was measured by a commer-
cially available immunoradiometric assay (Shionoria BNP
kit, Shionogi and Co., Ltd.) (11). Plasma endothelin levels
were measured by a commercially available radioimmuno-
assay as previously described (4). Norepinephrine was de-
termined by radioenzymatic assay (12). Serum sodium,
plasma renin activity and aldosterone were also measured to
assess the activity of the renin-angiotensin-aldosterone sys-
tem. Plasma renin activity was assessed by radioimmunoas-
say measurement of angiotensin I generation (13). Aldoste-
rone was measured by radioimmunoassay (Cost-A-Count,
Diagnostic Products, Los Angeles, California). Blood urea
nitrogen and creatinine were measured to assess the impact
of therapy on renal function.
Statistical analysis. Data are expressed as mean  stan-
dard error. Changes in central hemodynamic measurements
were compared using a paired, two-tailed Student t test with
a Bonferroni correction for multiple comparisons. Neuro-
hormone levels were compared using a one-way analysis of
variance with repeated measures. Only subjects with data
available at both of the indicated time points were included
in each comparison. Statistical significance was accepted at
the 95% confidence interval (p  0.05).
RESULTS
Characteristics of the study population. The participants
included 34 patients with HF, 28 men and 6 women, age
52 2 years. All were admitted to the hospital for intensive
medical therapy. Each patient had symptoms of HF for
more than six months. Twenty-three patients were NYHA
class IV, and 11 patients were class IIIB. The average LV
ejection fraction was 20%  1%, determined by echocardi-
ography. Two patients had mild mitral regurgitation, 31 had
moderate regurgitation, and one had severe regurgitation as
estimated by the color flow Doppler technique. In the 20
patients able to perform an exercise test within 48 h of
baseline hemodynamics, the average peak oxygen consump-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
HF  heart failure
LV  left ventricle/ventricular
N-ANP  N-terminal fragment of atrial natriuretic
peptide prohormone
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tion was 10.2  0.8 ml/min/kg. The etiology of LV
dysfunction was coronary artery disease in 13 patients,
idiopathic cardiomyopathy in 16 patients, familial cardio-
myopathy in three patients, valvular disease in one patient
and peripartum cardiomyopathy in one patient (Table 1).
Hemodynamic response to therapy. Medical therapy tai-
lored to reduce filling pressures resulted in a fall in pulmo-
nary capillary wedge pressure from 31  1 to 18  1 mm
Hg, right atrial pressure from 15  1 to 8  1 mm Hg,
systemic vascular resistance from 1,780  94 to 1,109 
50 dynes/s/cm5 and mean systemic arterial pressure from
84  2 to 77  2 mm Hg (all p  0.05). Although they
were not specific targets of therapy, pulmonary vascular
resistance decreased from 316  37 to 174  22 dynes/s/
cm5, and cardiac index increased from 1.70  0.08 to
2.58  0.09 l/min/m2 (Table 2). The mean doses of
captopril before and after tailored therapy were 77 
14 mg/day and 134  18 mg/day, respectively (p  0.002),
and the mean doses of isosorbide dinitrate before and after
therapy were 10  5 mg/day and 50  7 mg/day, respec-
tively (p  0.01) (Table 2). Four subjects began to receive
hydralazine during treatment. No patient received an intra-
venous inotropic agent or a beta-receptor antagonist at
baseline or during the study.
Responses of renal function, the renin angiotensin sys-
tem, norepinephrine and endothelin. Sodium levels were
not significantly different after therapy (137  1 mmol/l
before and 136  1 mmol/l after therapy, p  0.07). Serum
creatinine and blood urea nitrogen were also unchanged
(1.2  0.1 to 1.1  0.1 mg/dl, p  0.63; and 27  2 to
28  2 mg/dl, p  0.62, respectively).
Angiotensin-converting enzyme inhibitors were withheld
between time points A and B then re-introduced between
time points B and C. Aldosterone levels increased signifi-
cantly between time points A and B, from 16.5  3.4 to
28.8  5.9 ng/dl (p  0.02), but they then decreased to
baseline levels at time point C, 16.3 3.2 ng/dl. As subjects
underwent progressive diuresis, plasma renin activity in-
creased from 15.4  2.2 ng/ml/h at time point A to 30.4 
1.8 ng/ml/h at time point B (p  0.0006) and remained
elevated at time point C, after ACE inhibitors had been
re-introduced, 32.0  1.4 ng/ml/h (p  0.0001) (Fig. 1).
Norepinephrine levels were not significantly different
between time points A (858  96 pg/ml) and B (817 
97 pg/ml) (p  0.60) after 1.4 days. By 3.4 days (time point
C), however, norepinephrine levels were significantly lower
(608  47 pg/ml, p  0.005) (Fig. 2). Mean dopamine and
epinephrine levels were unchanged after therapy.
Endothelin levels declined by 30% with intravenous
therapy from 7.7  0.6 to 5.5  0.5 pg/ml (p  0.004) and
remained low at time point C, 5.2  0.3 pg/ml (p  0.001)
(Fig. 3).
Response to therapy of the natriuretic peptides. As
expected from a large reduction in filling pressures, plasma
ANP levels fell by 52% from 201  30 to 96  14 pmol/l
(p  0.001) after intravenous therapy, and they remained
low, at 74 12 pmol/l (p 0.001), after titration to an oral
regimen. Levels of N-ANP also fell from 3,882  326 to
2,790  333 pmol/l at time point B (p  0.001) and to
2,575 295 pmol/l at time point C (p 0.007). The mean
plasma BNP level rapidly fell by 26%, from 175  22 to
126 20, after only 1.4 days of therapy (p 0.001) and fell
further to 82  13 pmol/l at time point C (p  0.001) (Fig.
4). It was not possible to demonstrate correlation between
the decrease in BNP and the amount of change in weight or
right atrial pressure, as all parameters improved in all
patients studied.
DISCUSSION
This study demonstrates that intervention to improve he-
modynamic status with diuretics and vasodilators acutely
modifies markers of neurohormonal activation in patients
with a severe degree of resting hemodynamic compromise.
Endothelin and natriuretic peptide levels rapidly decrease
after medical therapy designed to reduce filling pressures.
Table 2. Hemodynamics and Medical Regimens Before and
After Therapy
Pre-treatment Post-treatment
Hemodynamics
MAP (mm Hg) 84  2 77  2*
RAP (mm Hg) 15  1 8  1*
PAP (mm Hg) 44  2 29  1*
PCWP (mm Hg) 31  1 18  1*
SVR (dynes/s/cm5) 1780  94 1109  50*
PVR (dynes/s/cm5) 316  33 174  22*
CI (l/min/m2) 1.70  0.08 2.58  0.09*
HR (beats/min) 89  3 86  3
Medication mg/day
Captopril (n  33) 77  14 134  18*
Isosorbide dinitrate (n  29) 10  5 50  7*
Hydralazine (n  4) 0 23  11*
Furosemide (n  34) 183  19 229  22
*p  0.05.
CI  cardiac index; HR  heart rate; MAP  mean arterial pressure; PAP 
mean pulmonary artery pressure; PCWP  pulmonary capillary wedge pressure;
PVR  pulmonary vascular resistance; SVR  system vascular resistance
Table 1. Patient Characteristics
Age 52  2
Gender 28 men, 6 women
NYHA class
III B 11
IV 23
Mitral regurgitation
Mild 2
Moderate 31
Severe 1
Peak VO2 (n  20) (ml/min per kg) 10.2  0.8
Etiology
Ischemic 13
Idiopathic 16
Familial 3
Valvular 1
Peripartum 1
NYHA  New York Heart Association.
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Norepinephrine levels also show a decline in hospital but are
slightly delayed. Heart failure is characterized by activation
of a broad range of neurohormonal systems. Elevated levels
of vasoconstrictor hormones adversely effect remodeling and
disease progression. Vasodilator hormones may provide a
counter-regulatory influence. Current treatment of HF
focuses on direct antagonism of neurohormonal systems in
an effort to attenuate progression of disease, whereas the
main benefit of therapy that improves hemodynamics is
often considered to be relief of symptoms. The data pre-
sented here highlight the importance of optimizing hemo-
dynamics, a strategy specifically directed at decreasing ele-
vated filling pressures and vascular resistance, not only to
relieve symptoms but also to attenuate intense neurohor-
monal activation.
Sympathetic nervous system activation and response.
Plasma norepinephrine levels, markers of sympathetic ner-
vous system activation, increase in HF (14) and correlate
inversely with prognosis (2), contributing to progression of
HF by a variety of potential mechanisms including direct
myocardial toxicity, renal sodium and water retention,
peripheral vasoconstriction, induction of apoptosis, activa-
tion of the renin-angiotensin system or stimulation of
arrhythmias. In subjects with HF, norepinephrine levels
decreased coincident with the symptomatic improvement
associated with diuresis alone over a one-month period (15),
and they decreased also with long-term administration of
ACE inhibitors and beta-blocking agents (6–8). Hemody-
namic therapy resulting in lower filling pressures from
ultrafiltration or LV assist device implantation has also been
shown to decrease norepinephrine concentrations after three
months or more (9,16).
The current data indicate a trend toward a rapid fall in
venous plasma norepinephrine concentration that is appar-
ent after 3.4  0.4 days. Importantly, the time course over
which norepinephrine falls may be longer than that for the
endogenous vasodilator hormones. The earlier fall in vaso-
dilator substances before a decline in norepinephrine may
impact short-term responses to therapy for severe HF. It is
possible that some patients tolerate these short-term reduc-
tions in filling pressures poorly because of the initial
persistence of norepinephrine elevation, as endogenous
vasodilators such as the natriuretic peptides are attenuated
more rapidly.
The endothelin system and HF. Endothelin is a potent
endogenous vasoconstrictor peptide that is elevated in a
number of disease states, including pulmonary hypertension
and HF, in which the plasma levels have been correlated
with prognosis and central hemodynamics (17–19). Cat-
echolamines, angiotensin II and arginine vasopressin all
stimulate endothelin synthesis (20,21), and endothelin
clearance is decreased in HF (22). Endothelin, like the
catecholamines, may help support blood pressure for the
acutely failing heart, but it contributes to myocardial remod-
eling and causes vasoconstriction in coronary, pulmonary
and peripheral vascular beds (23–26). Endothelin also may
stimulate endogenous production of ANP, which may
modulate cardiac and vascular effects of endothelin (27).
This study of advanced HF showed that intensive hemo-
dynamic therapy focused on lowering intracardiac ventric-
ular filling pressures significantly lowered circulating
endothelin-1 levels over 3.4  0.4 days in severely compro-
mised patients, although it is not clear whether the change
reflects decreased production or increased clearance, both of
Figure 2. Effect of therapy on plasma norepinephrine levels before inter-
vention (A), after intravenous vasodilators and diuretics (B) and after
transition to an oral regimen (C). *p  0.05 compared to A.
Figure 3. Effect of therapy on plasma endothelin levels before intervention
(A), after intravenous vasodilators and diuretics (B) and after transition to
an oral regimen (C). *p  0.05 compared to A.
Figure 1. Effect of therapy on plasma aldosterone levels (left) and plasma renin activity (right) before intervention (A), after intravenous vasodilators and
diuretics (B) and after transition to an oral regimen, including captopril (C). *p  0.05 compared to A.
1626 Johnson et al. JACC Vol. 39, No. 10, 2002
Neurohormones and HF Therapy May 15, 2002:1623–9
which may contribute (28). Reduction of endothelin may
also contribute to lower natriuretic peptide levels.
The regulation of the renin-angiotensin-aldosterone sys-
tem. In HF, increased plasma renin activity is associated
with institution of diuretic therapy (29). Many studies in
patients with LV dysfunction have shown decreased mor-
tality with ACE inhibition (30–32). The intensive therapy
studied here includes significant diuresis and vasodilation to
optimize loading conditions. As expected, initial cessation
of ACE inhibition and simultaneous diuresis resulted in
higher plasma renin activity and aldosterone levels at time
point B. With additional diuresis and reinstitution of
converting enzyme inhibition by time point C, plasma renin
activity remained elevated, but aldosterone levels fell to their
baseline values. The net change in this system is complex
and may also reflect changing natriuretic peptide levels and
later enhanced dosing of ACE inhibitors. In spite of
diuresis, vasodilation and marked lowering of filling pres-
sures, there was no evidence of enhanced activation of the
renin-angiotensin-aldosterone system.
Natriuretic peptide regulation in HF. Atrial natriuretic
peptide and BNP are vasoactive peptides produced chiefly
by atrial myocytes and ventricular myocytes, respectively, in
normal humans (33). Both are released in response to
chamber wall tension and have important natriuretic and
vasodilatory effects (33–37). Plasma ANP and BNP are
increased in HF and correlate with atrial filling pressures
and disease severity (33,36,38). In addition to vasodilator
effects, ANP and BNP have been shown to suppress renin
release and decrease angiotensin II and aldosterone produc-
tion (39).
The vasodilatory effect of natriuretic peptides is blunted
in both animal and human studies of severe HF (34,40),
perhaps through alterations of receptor density, increased
local clearance or uncoupling of intracellular signaling trans-
duction pathways (41–43). Our data indicate that in pa-
tients with severe, decompensated HF, natriuretic peptide
levels can be rapidly reduced with therapy designed to lower
ventricular filling pressures, as has been shown with the
bedside BNP assay (38). This could cause transient impair-
ment of natriuresis and systemic vasodilation, and this effect
must be considered when achieving rapid normalization of
filling pressures. It is not known whether a longer-term
reduction of circulating natriuretic peptide levels may nor-
malize receptor density or function, and volume responsive-
ness (44).
The rapid changes in natriuretic peptides with reduction
of filling pressures lend support to the evolving concept that
these levels may be useful in evaluating a given patient’s
hemodynamic status during therapeutic interventions (44).
However, the brisk decline of these vasodilator and natri-
uretic peptides, which occurs more rapidly than the decline
in norepinephrine, may lead to a period of relative systemic
and regional hemodynamic instability with deficient endog-
enous vasodilation while awaiting reductions in endogenous
vasoconstrictors. It remains to be seen whether those with
the steepest early drops in BNP levels are at highest risk for
adverse events, particularly aggravated renal dysfunction
(45).
Limitations. The severity of illness of the patients studied,
as indicated by the resting hemodynamics, prevents gener-
alization of these study results to patients with a milder
degree of hemodynamic compromise. Beta-blocking agents
were not used in severe HF at the time of this study.
Neurohormonal measurements were not obtained in un-
treated patients to serve as controls. The third time point
occurred after re-initiation of the ACE inhibitor, typically
at a higher dose than before therapy. Although this may
have some effect on the neurohormonal milieu, most
changes observed occurred before ACE inhibitor treatment
was restarted, and time point C reflects changes shortly after
the ACE inhibitor was re-introduced. Lastly, the study was
designed to utilize hemodynamic information to better
understand the changes during therapy, but it was not
designed to assess the utility of therapy guided by hemody-
namic measurement.
Implications. This study demonstrates that neurohor-
monal activation, as reflected in plasma levels of endothelin,
ANP and BNP, rapidly decreases after intensive therapy
tailored to improve loading conditions, while norepineph-
rine levels also decline, but may respond over a slightly
longer time course. The rapid decline of neurohormonal
occurred without the need for intravenous inotropic therapy,
despite the severe hemodynamic compromise.
This study defines the extent to which these neurohor-
mones may change during vasodilator and diuretic therapy
for resting hemodynamic decompensation. Moreover, these
data support the use of natriuretic peptide levels as markers
Figure 4. Effect of therapy on plasma levels of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) (left), and N-terminal pro-ANP (N-ANP)
(right) before intervention (A), after intravenous vasodilators and diuretics (B) and after transition to an oral regimen (C). *p  0.05 compared to A.
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of circulatory decompensation. The differing time course of
the vasodilator hormones, BNP and ANP, and the vaso-
constrictor hormone, norepinephrine, could create a tran-
sient period of endogenous vasoconstrictor dominance po-
tentially compromising re-establishment of optimal volume
status, particularly while influencing intrarenal hemody-
namics. When resting hemodynamics are severely compro-
mised, therapy specifically designed to improve loading
conditions may serve as an important adjunct to neurohor-
monal antagonists and may facilitate subsequent titration of
such medications after stabilization.
Reprint requests and correspondence: Dr. Lynne W. Steven-
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